On the Radar
SEC Reporting Considerations for
Equity Method Investees
SEC registrants may have equity method investments, including those
accounted for under the fair value option or hypothetical liquidation basis. In
their filings with the SEC, they are required to provide financial information about
any significant equity method investees. Therefore, such registrants must consider
whether to provide financial information about such investee in any report filed
with the SEC that includes their own financial statements.
Evaluating Equity Method Investments
A registrant is required to identify all investments accounted
for under the equity method. For each of those investments, it should measure
their significance by using the applicable tests and thresholds under SEC
Regulation S-X, Rules 3-09, 4-08(g), and 10-01(b)(1). If an equity method
investee is considered significant to a registrant, the registrant may be
required to provide either or both of the following:
-
Separate financial statements of the investee.
-
Summarized financial information of the investee in the footnotes to the registrant’s financial statements.
The registrant may also need to provide summarized income
statement information in its interim financial statements.
Level of Significance
The amount of information a registrant must present about an
investee depends on the investee’s significance level. To determine the
significance level, a registrant performs the applicable tests (as indicated
below) for each equity method investee individually and, in certain cases, for
all such investees in the aggregate:
-
The investment test — The registrant’s and its other subsidiaries’ investments in and advances to the tested equity method investment are compared with the total consolidated assets of the registrant as of the end of the most recently completed fiscal year.
-
The asset test — The registrant compares its share of the investee’s assets with the registrant’s consolidated total assets. Such amounts are generally as of the most recently completed fiscal year for both the investee and the registrant.
-
The income test — The test has two components:
- Income component — The absolute value of the registrant’s proportionate share of the investee’s pretax income or loss from continuing operations is compared with the absolute value of the registrant’s own pretax income or loss from continuing operations.
- Revenue component — If both the registrant and the investee have material revenue in each of the two most recently completed fiscal years, the revenue component is calculated by comparing the registrant’s proportionate share of the investee’s revenue with the registrant’s revenue. The determination of whether the investee has material revenue is separate from the determination of whether the registrant has material revenue.
An investee will only be considered significant under the income test if both the income component and the revenue component (if applicable) exceed the significance threshold. When both components exceed the significance threshold, the lower of the income or revenue component is used to determine significance in accordance with the income test.
The test that results in the highest significance level will be
used to establish the financial reporting requirements. A registrant may use the
following table to determine which information must be presented:
The SEC staff may
issue comments related to how a registrant complied
with SEC rules and ask the registrant to provide the
calculations it used in performing the significance
tests.
Separate Financial Statements
When separate financial statements of the investee are required,
a registrant must present such statements as of and for the same periods as the
registrant’s financial statements unless the registrant did not account for the
investment by using the equity method for the whole period for which its
financial statements are required. In such cases, the investee’s financial
statements should only be presented for the periods in which the investee was
accounted for under the equity method, which may result in partial-year
financial statements.
The financial statements for the period in which the
significance test has been met must also be audited by an accountant that is
independent under SEC rules. The audits can typically be performed in accordance
with AICPA standards, but in some instances PCAOB standards apply.
The form and content
of the financial statements, including the schedule
requirements, must comply with Regulation S-X.
Summarized Financial Information
Under SEC rules, to determine whether it must provide summarized
financial information in its annual financial statements, the registrant
performs the applicable significance tests on all equity method investees
individually and as part of an aggregated group.
When deemed significant under the applicable tests, the
registrant’s annual financial statements must include summarized financial
information for all equity method investees. Such information should not be
labeled “unaudited.”
To determine whether it must provide summarized income statement
information in its interim financial statements, the registrant performs the
applicable significance tests for each equity method investee individually. The
registrant’s interim financial statements must include summarized income
statement information of an equity method investee only if the investee is
significant to the registrant during the interim period.
When acquiring an equity interest in an entity, the
registrant may want to incorporate the ongoing SEC
reporting requirements related to equity method
investees into the purchase agreement to ensure that the
investee will be able to make the required financial
information available within the timeline required by
such rules.
Other Considerations
In March 2023, the FASB issued ASU 2023-02, which expands the
applicability of the proportional amortization method (PAM) to investments that
would otherwise be accounted for under the equity method of accounting.
Registrants that have material investments and have elected the accounting
policy choice to apply PAM may consider consulting with their audit and legal
professionals and reaching out to the SEC to discuss their fact patterns.
In addition to ASU 2023-02 as well as the requirements discussed
above, a registrant should consider the following:
-
If it reports a discontinued operation retrospectively, the registrant will need to reevaluate the significance of its equity method investees for all periods.
-
It may wish to ask the SEC for a waiver if an equity method investee becomes significant because of unusual circumstances.
-
Smaller reporting companies have different reporting requirements related to significant equity method investments.
-
The separate financial statements of a significant equity method investee may be included in the annual report filed by the registrant or in an amendment to the annual report depending on a number of considerations, including the equity method investee’s year-end and filing status and whether the investee is a foreign business.
-
When applying the income test to equity method investees for which a registrant has elected the fair value option in accordance with ASC 825-10-15-4, the registrant should calculate the income and revenue components as follows:
-
Income component — Determine by using the change in fair value of the investee reflected in the registrant’s income statement.
-
Revenue component — Determine by using the registrant’s proportionate share of the investee’s revenue (i.e., the registrant’s ownership interest in the investee multiplied by the investee’s revenue).
-
Deloitte’s Roadmap SEC
Reporting Considerations for Equity Method
Investees provides comprehensive
guidance on this topic. For guidance on the U.S. GAAP
requirements related to equity method investees, see
Deloitte’s Roadmap Equity Method Investments
and Joint Ventures.
Contacts
|
John Wilde
Audit &
Assurance
Partner
Deloitte &
Touche LLP
+1 415 783
6613
|
For information about Deloitte’s
SEC service offerings related to equity method investees, please contact:
|
Matt Burley
Audit &
Assurance
Partner
Deloitte &
Touche LLP
+1 720 264
4866
|